(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.09% HKD 2.77
Live Chart Being Loaded With Signals
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...
Stats | |
---|---|
Tagesvolumen | 39.49M |
Durchschnittsvolumen | 52.37M |
Marktkapitalisierung | 50.97B |
EPS | HKD0 ( 2024-03-29 ) |
Nächstes Ertragsdatum | ( HKD0 ) 2024-06-14 |
Last Dividend | HKD0.0600 ( 2023-06-20 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 25.18 |
ATR14 | HKD0.00800 (0.29%) |
Volumen Korrelation
Sino Biopharmaceutical Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Sino Biopharmaceutical Korrelation - Währung/Rohstoff
Sino Biopharmaceutical Finanzdaten
Annual | 2023 |
Umsatz: | HKD26.20B |
Bruttogewinn: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2023 |
Umsatz: | HKD26.20B |
Bruttogewinn: | HKD21.21B (80.95 %) |
EPS: | HKD0.0997 |
FY | 2022 |
Umsatz: | HKD28.78B |
Bruttogewinn: | HKD22.98B (79.86 %) |
EPS: | HKD0.270 |
FY | 2021 |
Umsatz: | HKD26.86B |
Bruttogewinn: | HKD21.53B (80.15 %) |
EPS: | HKD0.780 |
Financial Reports:
No articles found.
Sino Biopharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00198 | 2004-09-16 |
Last Dividend | HKD0.0600 | 2023-06-20 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 70 | -- |
Total Paid Out | HKD0.573 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.91 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.14 | |
Div. Directional Score | 7.37 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2362.HK | No Dividend Player | 2023-06-01 | Annually | 0 | 0.00% | |
1349.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
0393.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
6677.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
1899.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
0927.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0057.HK | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
2883.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
1480.HK | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0711 | 1.500 | 8.58 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0247 | 1.200 | 9.18 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0519 | 1.500 | -0.534 | -0.801 | [0.1 - 1] |
payoutRatioTTM | 0.404 | -1.000 | 5.96 | -5.96 | [0 - 1] |
currentRatioTTM | 1.053 | 0.800 | 9.73 | 7.79 | [1 - 3] |
quickRatioTTM | 0.755 | 0.800 | -0.263 | -0.210 | [0.8 - 2.5] |
cashRatioTTM | 0.418 | 1.500 | 8.79 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.197 | -1.500 | 6.72 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.410 | -1.500 | 8.36 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.788 | 1.000 | 0.197 | 0.197 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.203 | 1.000 | 7.94 | 7.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.306 | 1.000 | 9.41 | 9.41 | [0.2 - 2] |
assetTurnoverTTM | 0.347 | 0.800 | -1.020 | -0.816 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.82 | 1.000 | 6.89 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0519 | 2.50 | -0.343 | -0.801 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.404 | 1.500 | 5.96 | -5.96 | [0 - 1] |
pegRatioTTM | 0.329 | 1.500 | -1.141 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.174 | 1.000 | 8.16 | 0 | [0.1 - 0.5] |
Total Score | 5.14 |
Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.